Drugs / NC318
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT04430933 | Dec 2021 → Jun 2022 | non-small cell lung carcinoma | NextCure, Inc. | Withdrawn | No outcome recorded |
| Phase 1/2 | NCT03665285 | Oct 2018 → Apr 2023 | breast cancer, cholangiocarcinoma, endometrial cancer, head and neck squamous cell carcinoma +3 | NextCure, Inc. | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT04699123 | Feb 2021 → Jun 2025 overdue | non-small cell lung carcinoma | Yale University | Active not recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NC318 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04699123 ↗ |
| Modality | Monoclonal antibody | “NC318 is an experimental antibody drug that may make the immune response more active against cancer.” NCT03665285 ↗ |
| Route | Intravenous | “Subjects received NC318 IV at 8mg Q2W” NCT03665285 ↗ |